Unum’s leadership possesses biotech and large pharma drug development experience and deep scientific expertise in cancer immunotherapy. It includes pioneers in the field who created the CAR-T approach now pursued by several companies and those who led the first large pharma effort to develop such therapies.
Charles "Chuck" Wilson, PhD
Chuck leads the company. Before founding Unum, Chuck led partnering for Novartis research, and was responsible for all efforts in drug discovery up through Phase II clinical development. He brings to Unum deal experience in biotech and academic collaborations, product in-licensing, spin-outs, and strategic equity investing in early stage companies. Prior to Novartis, Chuck held both scientific and business management roles in biotechnology. Chuck received his PhD from the University of California, San Francisco, and completed his post-doctoral training at Harvard University / Massachusetts General Hospital.
Chief Financial Officer and Head of Corporate Development
Christiana is responsible for leading Unum’s financial strategy, capital-raising activities, and the forging of business development partnerships. She brings extensive experience in developing strategies for growth, strategic collaborations and capital-raising transactions. Christiana most recently served as SVP and Head of Corporate Strategy and Business Development at Vertex Pharmaceuticals, where she helped develop the company’s vision, corporate strategy and the identification and execution of its strategic business collaborations. Prior to Vertex, Christiana was a senior investment banker with Goldman Sachs and Citigroup. Christiana received her Bachelors of Science and MBA from the Massachusetts Institute of Technology.
Chief Technical Officer
Geoff is responsible for leading Unum’s technical and non-technical operations, including groups in manufacturing, process development, analytics, and quality. He has over 25 years of experience in the biotechnology industry, providing bioprocessing innovation and operations leadership for companies including Millennium Pharmaceuticals, Genetics Institute, and Alpha-Beta Technology. Prior to joining Unum, Geoff was a co-founder of Xcellerex and operations leader at Xcellerex/GE Healthcare Lifesciences. He received his Bachelors of Arts at Colgate University and Masters of Science from Worcester Polytechnic Institute.
Seth Ettenberg, PhD
Chief Scientific Officer
Seth is a cancer biologist and drug development scientist with experience leading teams in biotechnology and large pharmaceutical drug discovery settings. He brings a strong track record of immuno-oncology experience to Unum, having taken multiple biologics programs through clinical development during his career. Seth most recently served as Head of Novartis Oncology Biotherapeutics, Cambridge Site. Seth received his PhD from the Uniform Services University of the Health Sciences and completed his post-doctoral training at the National Cancer Institute.
Michael Vasconcelles, MD
Chief Medical Officer
Michael is responsible for defining the strategic vision and leading the execution of Unum’s clinical program. An industry veteran with extensive experience in managing multiple clinical programs, he previously served as Senior Vice President and Global Head for Oncology at Takeda Pharmaceuticals. While there, he led the development of the oncology portfolio from candidate selection through life cycle management. Michael also serves as a Clinical Instructor in Medicine at Harvard Medical School and a staff physician at the Dana-Farber Cancer Institute and Brigham & Women’s Hospital. He received his Bachelor of Arts and MD from Northwestern University.
Dario Campana, MD, PhD
Dario is the scientific founder of the company, and a leader in the field of cancer cell therapies. At the National University of Singapore (NUS), Dario developed the ACTR technology that forms the basis for Unum. At St. Jude Children’s Research Hospital, he created the CD19 chimeric antigen receptor (CAR) that was subsequently shown to be highly effective in treating patients with Acute Lymphoblastic Leukemia (ALL), an aggressive form of the disease. He has extensive experience managing clinical cell therapy trials in oncology. He received his MD from the University of Torino and his PhD from the University of Milan.